Development of a commercial point-of-care device capable of electronically sensing tumor cells and molecular cancer biomarkers in the circulating peripheral blood based panel on the molecular…
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201100068C
- Awardee
-
Molecular Express, Inc. UEI R1JMHFESEKD5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $197,673
Award facts
- Contract value 100% obligated
- $197,673.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 17 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- CRYSTAL CITY, CA 90220, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $197,673 |
About this award
This is a $197,673 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Molecular Express, Inc., a minority-owned and self-certified small disadvantaged business. The contract is for the development of a commercial point-of-care device capable of electronically sensing tumor cells and molecular cancer biomarkers in a patient's circulating peripheral blood. This research project is based on the molecular differences between the surfaces of normal and cancer cells. As an SBIR Phase I contract, it represents an initial feasibility study to explore the technical merit and commercial potential of this innovative cancer diagnostic technology.
Description
Development of a commercial point-of-care device capable of electronically sensing tumor cells and molecular cancer biomarkers in the circulating peripheral blood based panel on the molecular differences between the surfaces or normal and cancer cell of a patient.
Quick answers
Who was awarded contract HHSN261201100068C?
HHSN261201100068C was awarded to Molecular Express, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2011.
How much is contract HHSN261201100068C worth?
The government has obligated $197,673 on HHSN261201100068C.
Was contract HHSN261201100068C competed?
The extent of competition for HHSN261201100068C was full and open competition after exclusion of sources. The government received 17 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award